Everything You Need to Know About Valeant's Deal With Allergan

Before you go, we thought you'd like these...
Before you go close icon

Shares of pharmaceutical company Valeant  have remained steady today despite the recent drama surrounding its acquisition of Allergan  maker of Botox. According to Motley Fool analyst Michael Douglass, Valeant has been attempting to acquire Allergan for months now, but to no avail. However, Bill Ackman and his Pershing Square Capital fund own about 10% of Allergan, and Ackman has been pushing hard for a deal with Valeant -- in fact, he's called for the replacement of the majority of Allergan's board of directors in order to get the deal done.

So, what's an investor to do in the midst of all this back and forth? Valeant's way of doing business is to acquire other drugmakers that have products in late-stage trials and then bring those products to market for a profit. While this has worked for the company in the past, Michael doesn't think it's a good idea for investors to make a bet on an acquisition that may not work. If they think there's a good fundamental reason for investing in Valeant, as Michael does, then great; otherwise, stay away.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


The article Everything You Need to Know About Valeant's Deal With Allergan originally appeared on Fool.com.

Mark Reeth has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners